Quoin Pharmaceuticals Highlights Netherton Syndrome Patient Journey in New Video Campaign
Event summary
- Quoin Pharmaceuticals released a new episode in its NETHERTON NOW video series on September 10, 2026, featuring Aminah’s story told by her adoptive mother, Dr. Laura Wright-Sexton.
- Dr. Wright-Sexton, a pediatric critical care physician, first met Aminah as a critically ill Netherton Syndrome patient in the ICU before adopting her.
- Quoin’s lead product, QRX003, is currently in a Phase 2/3 clinical trial for Netherton Syndrome, with positive interim data released on August 28, 2026.
- NETHERTON NOW campaign aims to increase awareness of Netherton Syndrome among the public, physicians, and policymakers.
The big picture
Quoin Pharmaceuticals' latest video campaign underscores the company's dual focus on clinical development and patient advocacy, a strategy increasingly adopted by rare disease biopharmaceutical firms. The release of positive interim data for QRX003 positions Quoin to potentially capture a significant share of the Netherton Syndrome treatment market, which currently lacks FDA-approved therapies. The company's ability to leverage patient stories for awareness and regulatory support will be critical in its long-term success.
What we're watching
- Clinical Trial Progress
- How the positive interim data from the Phase 2/3 trial of QRX003 will impact the regulatory pathway and investor confidence.
- Patient Advocacy
- Whether the NETHERTON NOW campaign can effectively drive awareness and support for Netherton Syndrome among key stakeholders.
- Market Positioning
- The pace at which Quoin Pharmaceuticals can differentiate itself in the competitive landscape of rare disease treatments.